Insight Report 6 minutes PremiumWhat the Ozempic Economy Means for US Retail Anand Kumar, Associate Director of Research Sector Lead: Swarooprani Muralidhar, Director of Research and Managing Director of Healthcare November 20, 2023 What's InsideOzempic, a medication used to treat type 2 diabetes, is gaining strong momentum in the pharmaceutical market due to its ability to manage blood sugar levels and promote weight loss. The increased adoption of Ozempic and other drugs in the GLP-1 drug class reflects a broader consumer shift toward prioritizing health and wellness. We dive into the implications of widespread GLP-1 drug use on US retail, including the impacts on sectors such as grocery and apparel. Companies mentioned in this report include: Hershey, Lululemon Athletica, Mondelēz International, NIKE, PepsiCo, Walmart Other relevant research: Weinswig’s Weekly: Health Is Wealth Market Navigator: US Apparel and Footwear Retailing—After the Bounce, What’s Next? Generative AI for US Retail Pharmacies and Healthcare: Satisfying Customers through Automation and Personalization Visit the Coresight Research Food, Grocery and CPG Retail Hub to explore sector data, reports and company profiles. This report is for subscribers only. Learn more about subscriptions here.If you are a subscriber, please log in. This document was generated for Other research you may be interested in: Market Navigator: US CPG—Significant Growth Opportunities Amid a Dynamic LandscapeAlarming Return Rates Require Loss-Minimization Solutions: Key Insights—Free InfographicEarnings Insights 1Q23, Week 2: Colgate-Palmolive, CVS, Floor & Decor, L’Oréal and Sprouts Farmers Market Post Strong Results; Carter’s, Estée Lauder, Hanesbrands and Wayfair Sales DeclineUS Store Tracker Extra, August 2023: Retailers To Open 78 Million Square Feet of New Retail Space This Year
